Colorado PDAB Takes Precedent-Setting Steps That Could Spur Suits

Colorado’s Prescription Drug Affordability Board voted Friday (Feb. 16) that Amgen’s Enbrel, used to treat various forms of arthritis and psoriasis, is “unaffordable,” and that Gilead Sciences’ Genvoya, a medication for HIV, was “not unaffordable.” The board is set to determine whether it will impose an upper payment limit on Enbrel on Friday (Feb. 23) -- a potentially precedent-setting move that is being closely watched by drug-price control advocates and the drug industry as other states consider setting up similar...